Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04759937
Other study ID # Soh-Med-21-02-16
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 20, 2021
Est. completion date December 2021

Study information

Verified date October 2021
Source Sohag University
Contact khoulood Zakaria Hashem
Phone 01127936972
Email khoulood.zakaria@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Amoebiasis, an infection by the protozoan parasite Entamoeba histolytica is globally considered as the third leading parasitic cause of human mortality besides malaria and schistosomiasis. It is estimated that E. histolytica may infect half a billion people annually. Moreover, it was estimated that 100,000 patients per year died due to the clinical complications of the disease. Laboratory diagnosis of E. histolytica/dispar is usually achieved by microscopic detection of trophozoites or cysts in stool samples. Microscopy is time consuming and requires an experienced observer to identify the organism. Furthermore, it must be performed on three stool samples to increase sensitivity leading to decreased patient compliance and delay in the final diagnosis. Therefore, a few the commercially available copro-antigen assay have been developed for E. histolytica/dispar diagnosis including the enzyme immunoassay and non-enzymatic immunochromatographic (ICT) assays that do not depend on microscopy skills and increase laboratory efficiency by reducing time and cost. The aim of the study is: 1. to evaluate the efficacy of commercially available rapid immunochromatographic Copro-antigen assay (RIDA® QUICK Entamoeba) in comparison with conventional microscopic examination for the diagnosis of E. histolytica /dispar infection. 2. to estimate the prevalence of E. histolytica /dispar infection in outpatients in Sohag.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2021
Est. primary completion date October 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients complaining of dysentery or diarrhea with any age & sex groups. Exclusion Criteria: - Patients taking amoebicidal drugs.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Faculty of medicine-Sohag University Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluate the efficacy of immunochromatographic Copro-antigen assay for diagnosis of Entamoeba histolytica/ dispar. comparing the sensitivity and specifity with conventional microscopy for diagnosis of Entamoeba histolytica/ dispar infection. 16 weeks following the startpoint of the study.
Secondary detect the prevelance of Entamoeba histolytica/ dispar in Sohag. By examining stool samples from 100 patients, the number of cases with Entamoena histolytica/dispar infection is recorded. 16 weeks following the startpoint of the study.